Kessler Topaz is investigating potential claims on behalf of purchasers of GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx") common stock between September 23, 2020 and November 8, 2022, related to potential violations of the federal securities laws.
GoodRx operates a price comparison platform for prescription drugs which, in many cases, offers consumers access to lower prices for their medications. The company’s platform provides customers with discount codes and coupons that pharmacy benefit managers have negotiated with various pharmacies. GoodRx then receives a commission on the prescription purchases made through its platform.
Our investigation is focused on whether GoodRx misled investors about the sustainability of the company’s business model by concealing significant risks.
The final truth was revealed on November 8, 2022, when GoodRX shocked investors by revealing information relating to a severe impact to its revenue for the fourth quarter. On this news, the price of GoodRx common stock declined $1.18 per share, or more than 22%, from a close of $5.24 per share on November 8, 2022, to close at $4.06 per share on November 9, 2022.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com, or fill out the form below.